Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Identifying the window of aggressive postpartum breast cancer based on the 21-gene Oncotype DX® test in women with HR+, HER2-negative breast cancer.

NPJ breast cancer·2026
Same author

Receptor discordance between primary tumors and nodal metastases and correlation with the 21-gene recurrence score in early-stage, estrogen receptor-positive, node-positive breast cancer.

Breast cancer research and treatment·2026
Same author

Dynamic monitoring of antibody drug conjugates targeting TROP2 or HER2 in breast cancer using circulating tumor cells.

Proceedings of the National Academy of Sciences of the United States of America·2026
Same author

Activating a B cell immune response regresses immunologically cold tumours.

Nature nanotechnology·2026
Same author

A Patient-Led Survey of Antibody Drug Conjugate Usage and Dosing for People Living With Metastatic Breast Cancer.

Journal of patient experience·2026
Same author

Safety and antitumour activity of ipatasertib combined with endocrine therapy and a CDK4/6 inhibitor in HR+/HER2- metastatic breast cancer (TAKTIC): a single-centre, open-label, phase 1b trial.

The Lancet. Oncology·2026

Related Experiment Video

Updated: Apr 6, 2026

Performing Data Mining And Integrative Analysis Of Biomarker in Breast Cancer Using Multiple Publicly Accessible Databases
07:41

Performing Data Mining And Integrative Analysis Of Biomarker in Breast Cancer Using Multiple Publicly Accessible Databases

Published on: May 17, 2019

9.7K

Gene-Expression-Based Predictors for Breast Cancer.

Arjun Gupta1, Miriam Mutebi2, Aditya Bardia3

  • 1Department of Internal Medicine, University of Texas Southwestern Medical Center, Dallas, TX, USA.

Annals of Surgical Oncology
|July 29, 2015
PubMed
Summary
This summary is machine-generated.

Genomic tests help personalize early-stage hormone receptor-positive breast cancer treatment. These advancements may reduce chemotherapy use, potentially leading to chemotherapy-free options.

More Related Videos

Author Spotlight: Impact of Intergenic Interactions on Disease-Identifying Dark Biomarkers
03:37

Author Spotlight: Impact of Intergenic Interactions on Disease-Identifying Dark Biomarkers

Published on: March 1, 2024

1.5K
Optimization of a Multiplex RNA-based Expression Assay Using Breast Cancer Archival Material
11:12

Optimization of a Multiplex RNA-based Expression Assay Using Breast Cancer Archival Material

Published on: August 1, 2018

8.5K

Related Experiment Videos

Last Updated: Apr 6, 2026

Performing Data Mining And Integrative Analysis Of Biomarker in Breast Cancer Using Multiple Publicly Accessible Databases
07:41

Performing Data Mining And Integrative Analysis Of Biomarker in Breast Cancer Using Multiple Publicly Accessible Databases

Published on: May 17, 2019

9.7K
Author Spotlight: Impact of Intergenic Interactions on Disease-Identifying Dark Biomarkers
03:37

Author Spotlight: Impact of Intergenic Interactions on Disease-Identifying Dark Biomarkers

Published on: March 1, 2024

1.5K
Optimization of a Multiplex RNA-based Expression Assay Using Breast Cancer Archival Material
11:12

Optimization of a Multiplex RNA-based Expression Assay Using Breast Cancer Archival Material

Published on: August 1, 2018

8.5K

Area of Science:

  • Oncology
  • Genomics
  • Breast Cancer Research

Background:

  • Adjuvant chemotherapy decisions for early-stage hormone receptor-positive breast cancer are complex.
  • Traditional markers are supplemented by advanced genomic and predictive biomarkers.
  • Genomic tests are being explored in the neoadjuvant setting for earlier clinical benefit.

Purpose of the Study:

  • To review the role of gene expression-based predictors in early-stage breast cancer.
  • To provide an overview of future directions, including next-generation sequencing.
  • To discuss the potential for individualized therapy selection and reduced chemotherapy use.

Main Methods:

  • Review of landmark articles and current research in breast cancer genomics.
  • Analysis of mutational data using next-generation sequencing.
  • Evaluation of predictive biomarkers for treatment response.

Main Results:

  • Genomic tests offer prognostic and predictive capabilities for identifying patients benefiting from therapy.
  • Next-generation sequencing identifies molecular targets for novel targeted therapies.
  • Ongoing clinical trials are evaluating targeted therapies like PI3K inhibitors.

Conclusions:

  • Genomic-based predictors will increasingly guide individualized endocrine therapy selection and duration.
  • Targeted therapies, combined with genomic data, will be integrated into treatment strategies.
  • A significant decrease in chemotherapy use is anticipated, potentially leading to chemotherapy-free treatment for early-stage HR-positive breast cancer.